



Novel, first-in-class small molecule inhibitors
targeting tau for neurodegeneration



Robert Foerster, CFO
Jack Pasini, CCO


February 11, 2021

- **Emerging biotechnology company**


- **Employees:** 12
- **Founded:** 2006
- **Corporate Offices:** 2 Westchester Park Lane, Suite 208, West Harrison
- **Laboratories:** Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine
- **Focus:** Small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade. This is a critical step in the development of dementia diseases.




Global Dementia Prevalence Increase




Patient
Population
(millions)



Growing Cost of US Healthcare for Dementia



Healthcare
Cost
(\$ Billions)




VISION

To discover and develop novel small molecule Disease-Modifying Therapeutics and biomarkers for dementia by targeting tau self-association into oligomers.

- **Highly differentiated small molecule tau treatment:**
 - Represents a more economical, cost-effective therapeutic option compared with competitive antibody approaches targeting tau that are in development.
- Advanced its technologies using its equity investment, NIH grant awards.
- Built a sound business model around its core technologies, a strong intellectual property (IP) position and a very highly experienced management team.



Lead Compound Profile - OLX07010



- **First-in-class small molecule** inhibitor of tau self-association
- Demonstrated **in vivo proof-of-concept (POC)**
- Preparing to enter **first-in-human clinical development**
- Initial focus on **Rare diseases** in the clinic, then AD
- Patent Protection:
 - Small molecule **patents pending**
 - Four **issued patents** around target and biomarkers

WHY WESTCHESTER

- **Need driven** – outgrew Albert Einstein space
- **Economics** – better value /sqf
- **Location Convenience** – easy access for both employees and collaborators
- **Location flexibility** – opportunity for expansion
- **Quality** – up-to-date building

Please direct all inquiries to:

James Moe, Ph.D., MBA
President and CEO
Mobile: 646-373-6897
Email: jmoe@oligomerix.com

Jack Pasini
Chief Commercial Officer
Mobile: 917-912-4088
Email: jpasini@oligomerix.com